You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

Addition of ADA-SCID to newborn blood screening ‘not likely’ until 2022

By Dermot - 03rd Dec 2020 | 5 views

The addition of adenosine deaminase severe combined immunodeficiency (ADA-SCID) to the national newborn bloodspot screening programme will “likely” not take place until 2022, this newspaper has been told.

On 17 July, the national screening advisory committee (NSAC) approved the application of the national newborn bloodspot screening programme governance group for ADA -SCID to be added to the list of eight conditions screened in the existing programme. The NSAC then made a recommendation to Minister for Health Stephen Donnelly.

A HSE spokesperson said Minister Donnelly has since contacted the Executive to approve this recommendation. However, they said the addition may not take place until 2022.

“The addition of any new condition to the list of conditions that are screened for is a complex process requiring clinical, laboratory, technical, public health and project management expertise,” the HSE’s spokesperson told the Medical Independent.

“The HSE has started the planning process to achieve screening for ADA-SCID in the national newborn bloodspot screening programme. This includes submissions for funding to the annual service planning process that is part of the preparation of the annual financial estimates that is submitted to the Department of Health.

“Once this is confirmed, the relevant work streams can be implemented. It will likely be 2022 before screening is actually implemented, but no start date can be given at this stage.”

The role of the NSAC is to undertake an independent assessment of evidence for screening for a particular condition against internationally-accepted criteria and make recommendations.

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]